Horizon Kinetics Asset Management LLC Lowers Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Horizon Kinetics Asset Management LLC lessened its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 4.2% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 2,759 shares of the biopharmaceutical company’s stock after selling 121 shares during the period. Horizon Kinetics Asset Management LLC’s holdings in Alnylam Pharmaceuticals were worth $759,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in ALNY. Ashton Thomas Private Wealth LLC purchased a new position in shares of Alnylam Pharmaceuticals in the second quarter valued at $26,000. Huntington National Bank increased its holdings in shares of Alnylam Pharmaceuticals by 91.8% in the 3rd quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 45 shares during the last quarter. Hollencrest Capital Management bought a new position in shares of Alnylam Pharmaceuticals in the 3rd quarter valued at about $29,000. Washington Trust Advisors Inc. purchased a new position in Alnylam Pharmaceuticals in the third quarter worth about $42,000. Finally, Harvest Fund Management Co. Ltd bought a new stake in Alnylam Pharmaceuticals during the third quarter worth approximately $45,000. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have recently commented on ALNY shares. Cantor Fitzgerald reiterated a “neutral” rating and issued a $220.00 target price on shares of Alnylam Pharmaceuticals in a report on Friday, October 11th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $300.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Friday, November 1st. William Blair reissued an “outperform” rating on shares of Alnylam Pharmaceuticals in a research note on Tuesday, November 19th. Piper Sandler restated an “overweight” rating and issued a $296.00 target price on shares of Alnylam Pharmaceuticals in a report on Monday, November 18th. Finally, TD Cowen upped their price target on shares of Alnylam Pharmaceuticals from $282.00 to $371.00 and gave the company a “buy” rating in a report on Monday, October 21st. One analyst has rated the stock with a sell rating, five have given a hold rating and nineteen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $298.09.

Alnylam Pharmaceuticals Stock Performance

Shares of Alnylam Pharmaceuticals stock opened at $250.98 on Tuesday. The firm has a market cap of $32.37 billion, a P/E ratio of -95.79 and a beta of 0.39. The company has a current ratio of 2.75, a quick ratio of 2.69 and a debt-to-equity ratio of 31.64. Alnylam Pharmaceuticals, Inc. has a 12 month low of $141.98 and a 12 month high of $304.39. The stock’s fifty day moving average price is $273.13 and its 200-day moving average price is $238.67.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.36). The company had revenue of $500.90 million during the quarter, compared to the consensus estimate of $532.91 million. During the same quarter in the prior year, the firm posted $1.15 earnings per share. Alnylam Pharmaceuticals’s quarterly revenue was down 33.3% compared to the same quarter last year. On average, equities research analysts expect that Alnylam Pharmaceuticals, Inc. will post -2.21 earnings per share for the current fiscal year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.